Udayasankar Arulmani

Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

Alexander So, Marc De Meulemeester, A. Pikhlak et al. · Arthritis & Rheumatism · 2010 · 308 citations

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

Naomi Schlesinger, Eduardo Mysler, Hsiao‐Yi Lin et al. · Annals of the Rheumatic Diseases · 2011 · 236 citations · Full text

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Gerd‐Rüdiger Burmester, Alan Kivitz, H. Küpper et al. · Annals of the Rheumatic Diseases · 2014 · 226 citations · Full text

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Rieke Alten, Juan J. Gómez‐Reino, Patrick Durez et al. · BMC Musculoskeletal Disorders · 2011 · 149 citations · Full text

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Naomi Schlesinger, Marc De Meulemeester, A. Pikhlak et al. · Arthritis Research & Therapy · 2011 · 133 citations · Full text